Showing 3811-3820 of 8217 results for "".
- VISIBLE: Guselkumab Provides Scalp Psoriasis Relief in Diverse Skin Toneshttps://practicaldermatology.com/news/visible-guselkumab-provides-scalp-psoriasis-relief-in-diverse-skin-tones/2475455/Guselkumab 100 mg demonstrated efficacy and sustained improvement through 48 weeks in a cohort of adults with moderate to severe scalp psoriasis and skin of color, new research suggests. In the B cohort of the phase 3b, rand
- Hands On: Practical Tips for Diagnosing and Treating Chronic Hand Eczemahttps://practicaldermatology.com/news/hands-on-practical-tips-for-diagnosing-and-treating-chronic-hand-eczema/2475415/Despite its small body surface area involvement, chronic hand eczema (CHE) represents a significant dermatologic and socioeconomic burden. In a recent session on chronic hand eczema (CHE) Socity of Dermatology Physician Associates (SDPA) 2025 Summer Conference given by Adam Friedman, MD, FAAD, he
- ZORYVE Cream 0.15% Gets AAD Endorsement for Atopic Dermatitishttps://practicaldermatology.com/news/zoryve-cream-015-gets-aad-endorsement-for-atopic-dermatitis/2475411/The American Academy of Dermatology (AAD) has issued a strong recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adult patients with mild to moderate atopic dermatitis (AD), according to updated guidelines released June 26.
- Shifting the Perspective: Addressing Social Determinants and Pigmentary Impact in Atopic Dermatitishttps://practicaldermatology.com/news/shifting-the-perspective-addressing-social-determinants-and-pigmentary-impact-in-atopic-dermatitis/2475416/In her presentation “Viewing Atopic Dermatitis Through a Different Lens,” Candrice Heath, MD, FAAD, an associate professor of dermatology at Howard University, used atopic dermatitis (AD) as a case study to examine how social determinants of health (SDOH), skin tone diversity, and structural ineq
- Review: Air Quality and Weather Linked to Dermatitis Severityhttps://practicaldermatology.com/news/review-air-quality-and-weather-linked-to-dermatitis-severity/2475392/Increased exposure to air pollutants and extreme temperatures is associated with greater population burden of atopic dermatitis (AD), according to a systematic review published in JAMA Dermatology.
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- New Biomarkers Linked to Atopic Dermatitis Severityhttps://practicaldermatology.com/news/new-biomarkers-linked-to-atopic-dermatitis-severity/2475296/New data published in JID Innovations shows elevated levels of immune cells in patients with atopic dermatitis (AD).
- Dupilumab Linked to Higher Psoriasis Risk in AD Patientshttps://practicaldermatology.com/news/dupilumab-linked-to-higher-psoriasis-risk-in-ad-patients/2475230/Patients with atopic dermatitis (AD) prescribed dupilumab face a higher risk of developing psoriasis compared to those receiving other systemic agents, according to a large retrospective cohort study in JAMA Dermatology.
- Biosimilar STEQEYMA Now Approved for All Ustekinumab Dosage Forms, Strengthshttps://practicaldermatology.com/news/Biosimilar-STEQEYMA-Now-Approved-All-Ustekinumab-Dosage-Forms-Strengths/2475172/The US Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, according to a press release from Celltrion, Inc. The additional pre
- GALDA Co-Director Explains Organization's Work and Impacthttps://practicaldermatology.com/news/GALDA-Co-Director-Explains-Organizations-Work-Impact/2475171/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo